Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05534893 · ClinicalTrials.gov registry record · NA
Effect of Blueberries on Immunity
A NA study, sponsored by Loma Linda University.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
NCT05534893: Completed NA study, sponsored by Loma Linda University.
NCT05534893 is a NA study that has completed, run by Loma Linda University. The registered enrollment target is 52 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05534893, a NA study, has completed, sponsored by Loma Linda University.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
Study Summary
This research study will test the effects of Blueberries on immune functions in overweight older men and postmenopausal women
Primary Outcome
Immunophenotyping will be performed by flow cytometry to measure the number of T helper, T cytotoxic, Naïve and memory cells and B cells
Interventions
- DIETARY_SUPPLEMENT Blueberry powder group
- DIETARY_SUPPLEMENT Placebo powder group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2022-10-12 |
| Est. Completion | 2023-09-12 |
| Phase | NA |
What the finished NCT05534893 record still lists
NCT05534893 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Blueberry powder group is the first listed.
NCT05534893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05534893 about?
NCT05534893 is a clinical study titled "Effect of Blueberries on Immunity". This research study will test the effects of Blueberries on immune functions in overweight older men and postmenopausal women
What is the current status of trial NCT05534893?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2022-10-12. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05534893?
The interventions under investigation include: Blueberry powder group (DIETARY_SUPPLEMENT), Placebo powder group (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05534893?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05534893's enrollment target sits among peer trials
52 1272nd of 2000 higher than 722 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI